Edition:
India

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

43.54USD
15 Jul 2019
Change (% chg)

$0.29 (+0.67%)
Prev Close
$43.25
Open
$43.39
Day's High
$43.57
Day's Low
$42.70
Volume
67,107
Avg. Vol
148,097
52-wk High
$73.83
52-wk Low
$39.65

Latest Key Developments (Source: Significant Developments)

Emergent Announces FDA Approval Of Change In Storage Conditions And Transfer Of Manufacturing For Its Cholera Vaccine
Wednesday, 5 Jun 2019 

June 4 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES FDA APPROVAL OF CHANGE IN STORAGE CONDITIONS AND TRANSFER OF MANUFACTURING FOR ITS CHOLERA VACCINE.EMERGENT BIOSOLUTIONS - ANNOUNCED APPROVAL BY FDA OF PRIOR APPROVAL SUPPLEMENT SUBMITTED BY CO FOR ITS ORAL CHOLERA VACCINE, VAXCHORA.EMERGENT BIOSOLUTIONS - VAXCHORA PRIOR APPROVAL SUPPLEMENT SUPPORTS CHANGE IN STORAGE CONDITIONS OF THE VACCINE FROM FROZEN TO REFRIGERATED AT 2-8°C.EMERGENT BIOSOLUTIONS - VAXCHORA PRIOR APPROVAL SUPPLEMENT SUPPORTS TRANSFER OF THE BULK DRUG SUBSTANCE MANUFACTURING TO MANUFACTURING FACILITY IN BERN.  Full Article

Emergent Biosolutions Announces Preliminary 2018 Financial Results And Provides 2019 Financial Forecast
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2018 FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL FORECAST.SEES FY 2018 REVENUE $779 MILLION TO $784 MILLION.SEES Q1 2019 REVENUE $185 MILLION TO $205 MILLION.SEES FY 2018 REVENUE UP 39 PERCENT.FULL YEAR 2018 PRELIMINARY PERFORMANCE IN LINE WITH RECENTLY REVISED GUIDANCE.FY2018 REVENUE VIEW $779.0 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.45 -- REFINITIV IBES DATA.SEES 2019 TOTAL REVENUES $1,060 MILLION - $1,140 MILLION.SEES 2019 ADJUSTED EBITDA $280 - $310 MILLION.SEES 2019 ADJUSTED NET INCOME $150 MILLION - $180 MILLION.FOR FY 2018, ANTICIPATES NET INCOME OF $60 TO $64 MILLION AND ADJUSTED NET INCOME OF $117 TO $121 MILLION.FY2019 REVENUE VIEW $1.02 BILLION -- REFINITIV IBES DATA.  Full Article

Emergent BioSolutions - Co's Adapt Subsidiaries And Opiant Filed Complaint
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS SAYS CO'S ADAPT SUBSIDIARIES AND OPIANT FILED COMPLAINT FOR PATENT INFRINGEMENT AGAINST PERRIGO IN U.S. COURT - SEC FILING.EMERGENT BIOSOLUTIONS - PATENT INFRINGEMENT COMPLAINT FILED ARISING FROM PERRIGO'S ANDA FILING WITH FDA FOR GENERIC VERSION OF NARCAN NASAL SPRAY 4MG/SPRAY.  Full Article

Cepi Awards $36 Million Contract To Profectus Biosciences And Emergent Biosolutions
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Emergent BioSolutions Inc ::CEPI AWARDS CONTRACT WORTH UP TO $36 MILLION TO PROFECTUS BIOSCIENCES AND EMERGENT BIOSOLUTIONS TO DEVELOP LASSA VIRUS VACCINE.COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS - AS PER CONTRACT, PROFECTUS WILL RECEIVE DEVELOPMENT FUNDING FROM CEPI FOR ADVANCING ITS LASSA VIRUS VACCINE.  Full Article

Emergent Biosolutions Inc Files For Potential Mixed Shelf Offering
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING.  Full Article

Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​
Tuesday, 27 Mar 2018 

March 26 (Reuters) - Emergent BioSolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY.EMERGENT BIOSOLUTIONS INC - ‍APPOINTED RICHARD S. LINDAHL AS COMPANY'S NEW EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.EMERGENT BIOSOLUTIONS INC - PROMOTED ROBERT G. KRAMER SR. TO NEWLY-CREATED POSITION OF PRESIDENT AND CHIEF OPERATING OFFICER​.EMERGENT BIOSOLUTIONS - ‍LINDAHL MOST RECENTLY SERVED AS CFO AT CEB INC​.  Full Article

Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK.SEES FY 2017 REVENUE $555 MILLION TO $560 MILLION.SEES Q1 2018 REVENUE $145 MILLION TO $160 MILLION.SEES FY 2017 REVENUE UP 14 PERCENT.- FOR FULL YEAR 2017, ANTICIPATES CASH AND CASH EQUIVALENTS AT YEAR END OF ABOUT $180 MILLION.- SEES 2018 TOTAL REVENUES FROM $715 MILLION TO $755 MILLION.SEES 2018 ADJUSTED NET INCOME $110 MILLION TO $125 MILLION.- FULL YEAR 2017 ADJUSTED NET INCOME IS ANTICIPATED TO BE $92 TO $96 MILLION.- FOR FULL YEAR 2017, ANTICIPATES NET INCOME OF $80 TO $84 MILLION.SEES 2018 NET INCOME $95 MILLION TO $110 MILLION.FY2017 REVENUE VIEW $547.9 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $659.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Emergent Biosolutions Awarded Department Of National Defence Contract
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS AWARDED DEPARTMENT OF NATIONAL DEFENCE CONTRACT TO SUPPLY ANTHRASIL TO THE CANADIAN GOVERNMENT.HAS BEEN AWARDED CONTRACT BY DEPARTMENT OF NATIONAL DEFENCE VALUED AT ABOUT $8 MILLION TO DELIVER ANTHRASIL TO CANADIAN GOVERNMENT.  Full Article

Emergent Biosolutions reports third quarter results
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Emergent Biosolutions Inc :Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance.Q3 earnings per share $0.68.Q3 revenue $149.4 million versus I/B/E/S view $124.6 million.Q3 earnings per share view $0.41 -- Thomson Reuters I/B/E/S.Emergent Biosolutions Inc sees FY 2017 ‍total revenues $540 million to $560​ million.Emergent Biosolutions Inc sees ‍FY 2017 net income $70 million to $80​ million.Emergent Biosolutions Inc sees FY 2017 ‍adjusted net income $85 million to $95​ million.  Full Article